Inhibition of granulocyte migration by tiotropium bromide [PDF]
Respiratory Research, 2011 Study objectives Neutrophil influx into the airways is an important mechanism in the pathophysiology of the inflammatory process in the airways of patients with chronic obstructive pulmonary disease (COPD).
Randerath Winfried J +2 more
doaj +5 more sources
Tiotropium bromide as adjunct therapy in children with asthma: a clinical experience [PDF]
Allergy, Asthma & Clinical Immunology, 2021 Background The Global Initiative for Asthma has only recently added tiotropium bromide as adjunct controller therapy in severe asthma (Step 4 or 5) in adults (2015) and children (2019). Although not yet approved for pediatric use by Health Canada, it has
Zainab Ridha +6 more
doaj +2 more sources
Tiotropium Bromide Has a More Potent Effect Than Corticosteroid in the Acute Neutrophilic Asthma Mouse Model [PDF]
Tuberculosis and Respiratory Diseases, 2022 Background Neutrophilic asthma (NeuA) is usually resistant to corticosteroids. Tiotropium bromide (TIO) is a bronchodilator that is used as an add-on therapy to inhaled corticosteroid and long-acting β2 agonist in asthma treatment.
Tai Joon An +3 more
doaj +2 more sources
Legal demands of the tiotropium bromide for treatment of chronic obstructive pulmonary disease and their financial impact for the State of Paraná, Brazil [PDF]
Einstein (São Paulo), 2020 Objective To analyze the legal demands of tiotropium bromide to treat chronic obstructive pulmonary disease. Methods We included secondary data from the pharmaceutical care management systems made available by the Paraná State Drug Center.
Renata Szpak +4 more
doaj +2 more sources
Expression of Muscarinic Receptors and the Effect of Tiotropium Bromide in Aged Mouse Model of Chronic Asthma [PDF]
Tuberculosis and Respiratory Diseases, 2019 Background Efficacy and safety of tiotropium bromide, a muscarinic receptor antagonist, in treatment of asthma have been reported. However, its effect on airway remodeling in chronic asthma of the elderly has not been clearly verified.
Ji Young Kang, M.D., Ph.D. +6 more
doaj +2 more sources
Preparation and Evaluation of Mucus-Penetrating Inhalable Microparticles of Tiotropium Bromide Containing Sodium Glycocholate [PDF]
Pharmaceutics, 2022 This study aimed to prepare mucus-penetrating inhalable microparticles for dry powder inhalers and to evaluate their applicability in an asthma-induced rat model. Microparticles were prepared from water solutions containing tiotropium bromide, L-leucine,
Yong-Bin Kwon +5 more
doaj +2 more sources
A placebo-controlled, crossover trial to investigate the efficacy of tiotropium bromide or placebo added to usual care in stable symptomatic post-hematopoietic stem cell transplantation (HSCT) bronchiolitis obliterans syndrome (BOS) [PDF]
TrialsBackground Despite the fundamental progress in hematopoietic stem cell transplant, this treatment is also associated with complications. Graft-versus-host disease is a possible complication of HSCT.
Naeemeh Dini +6 more
doaj +2 more sources
Effect of Tiotropium Bromide on Airway Inflammation and Programmed Cell Death 5 in a Mouse Model of Ovalbumin-Induced Allergic Asthma [PDF]
Canadian Respiratory Journal, 2019 Rationale. We previously demonstrated increased expression of programmed cell death 5 (PDCD5) in asthmatic patients and ovalbumin-induced allergic asthma.
Juan Wang +3 more
doaj +2 more sources
Impact of Long-Term Tiotropium Bromide Therapy on Annual Lung Function Decline in Adult Patients with Cystic Fibrosis. [PDF]
PLoS ONE, 2016 Chronic lung disease is the leading cause of death in patients with Cystic Fibrosis (CF) and is often treated with bronchodilators. It is not known whether long-term tiotropium bromide treatment may have a positive impact on lung function.This ...
Claudia Brandt +5 more
doaj +2 more sources
Tiotropium bromide: an update. [PDF]
Open Respir Med J, 2009 Tiotropium bromide is a once-daily inhaled anticholinergic bronchodilator. It works by blocking the muscarinic receptors in airway smooth muscle. Tiotropium has a wide therapeutic margin, due to its poor gastrointestinal absorption and its very low systemic bioavailability. The drug is mainly indicated in COPD patients.
Heredia JL.
europepmc +4 more sources